Strong CAGR to Propel in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market and Beyond upto $2.44 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market From 2025 To 2029?
The market size of augmentation therapy for alpha-1 antitrypsin deficiency has experienced robust growth lately. Projected to rise from $1.69 billion in 2024 to $1.8 billion in 2025, it is expected to witness a compound annual growth rate (CAGR) of 6.2%. The significant surge in the historical period is primarily due to better diagnostic procedures, consciousness drives, clinical studies, and an ageing population.
There is anticipated robust expansion in the alpha-1 antitrypsin deficiency augmentation therapy market size over the forthcoming years, projecting a growth to$2.44 billion in 2029, at a compound annual growth rate (CAGR) of 7.9%. The predicted growth during the forecast period can be traced back to advancements and developments in telehealth, remote monitoring, precision medicine, and gene therapy. The forthcoming period is also expected to witness significant trends such as the accumulation of long-term safety and efficacy data, the adoption of patient-centered care models, tele-rehabilitation programs, and personalized dosing regimens.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13006&type=smp
Which Primay Drivers Are Accelerating Growth in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
The alpha-1 antitrypsin deficiency augmentation therapy market is experiencing growth due to a rise in respiratory illnesses. These are disorders that impact the lungs and respiratory system, causing difficulty breathing and reduced lung performance. This therapy aims to treat such diseases by supplementing the insufficient protein in individuals suffering from alpha-1 antitrypsin deficiency. The approach corrects the protease-antiprotease imbalance in the lungs, shielding lung tissue from damage due to unchecked neutrophil elastase activity and alleviating inflammation. For example, the Centers for Disease Control and Prevention, a US-based nationwide public health body, reported in March 2023 that there were 8,300 tuberculosis (TB) cases in the US in 2022, a surge from 7,874 cases in 2021. Hence, the escalating number of respiratory illnesses is fueling the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.
Which Primary Segments of the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Are Driving Growth and Industry Transformations?
The alpha-1 antitrypsin deficiency augmentation therapymarket covered in this report is segmented –
1) By Product Type: Glassia; Aralast NP; Prolastin C; Zemaira And Respreeza
2) By Route Of Administration: Oral; Injection; Inhalation
3) By End User: Hospitals; Specialty Clinics; Other End Users
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13006&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?# Market?
North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Which Technological Trends Are Reshaping the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Dynamics?
In an effort to maintain their market dominance in the acute respiratory distress syndrome (ARDS) sector, leading businesses are concentrating their energies on the invention of new therapeutic approaches, such as recombinant technology-based drug development. Utilizing recombinant DNA technology enables these companies to modify the DNA of living organisms to produce specific proteins, thereby creating pharmaceutical therapeutics. For instance, Inhibrx Inc., a US biotech firm, revealed in March 2022, that their product INBRX-101 had attained orphan drug status from the U.S. Food and Drug Administration (FDA) for addressing alpha-1 antitrypsin deficiency (AATD). INBRX-101, a recombinant human AAT-Fc fusion protein, that could potentially deliver a once-monthly dosage, is designed to safely reach and sustain AAT levels in line with those found in healthy individuals.
View the full report here:
What Parameters Are Used to Define the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market?
Alpha-1 antitrypsin deficiency augmentation therapy is a medical treatment that involves infusing purified alpha-1 antitrypsin protein into individuals with deficient levels to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes. It aims to slow the progression of emphysema and improve lung function in affected patients.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13006
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
